Unique ID issued by UMIN | UMIN000010791 |
---|---|
Receipt number | R000012440 |
Scientific Title | Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer |
Date of disclosure of the study information | 2013/05/23 |
Last modified on | 2014/05/23 16:52:56 |
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer (CR study in SHIGA)
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer (CR study in SHIGA)
Japan |
Rectal Cancer
Gastrointestinal surgery |
Malignancy
NO
Evaluation of the effectiveness and safety of the cetuximab+mFOLFOX6 combination therapy as the primary treatment for KRAS wildtype advanced rectal cancer
Efficacy
Phase II
Response Rate
Adverse effect (AE)
Progression free survival (PFS)
Disease control rate (DCR)
R0 resection rate
Rate of surgery
Time to Surgery (TTS)
Observational
20 | years-old | <= |
80 | years-old | >= |
Male and Female
(1) Histologically confirmed colorectal cancer
(2) Previously receive no chemotherapy for rectal cancer
(3) KRAS wild-type
(4) age 20-80 years patients
(5) ECOG performance status 0 or 1
(6) Patients with confirmed target lesion
(7) Patients have enough organ function for study treatment
WBC 3,000/mm3-12,000/mm3
Neutrophils>=1,500/mm3
Platelets>=100,000/mm3
Hemoglobin>=9.0g/dL
Total bilirubin<=1.5mg/dL
AST and ALT<=100 IU/L
Creatinine<=1.2mg/dL
Creatinine Clearance>=60mL/min
(8) Life expectancy of more than 3months
(9) Written informed consent from patients themselves
(1) History of serious drug hypersensitivity
(2) Women who are pregnant,or wish to become pregnant or men who expect babies
(3) Severe infectious disease (38degrees or higher)
(4) Serious complications
(5) Remarkably abnormal ECG,Clinically significant heart disease
(6) Gastrointestinal ulceration or bleeding
(7) Serious watery diarrhea
(8) Uncontrolable pleural effusion or ascites requiring treatment
(9) Cases with brain metastases or cases to doubt metastasis to brain from clinical manifestations
(10) Current or previous (within the last 6months) history of GI perforation
(11) Previous history of thrombosis,cerebra infarction,pulmonary infarction,hemoptysis (more than 2.5ml) and interstitial pneumonia
(12) Cases were operated within 28days before entry (Except for inserting central venous catheters and reservoir)
(13) Evidence of congenital bleeding diathesis or coagulopathy
(14) Ongoing treatment with anticoagulant
(15) Cases have active double cancer (disease free period is within five years)
(16) Continuous systemic administration of corticosteroids
(17) Patients judged inapproprite for this study by physicians
25
1st name | |
Middle name | |
Last name | Eiji Mekata |
Shiga University of Medical Science
Department of surgery
Seta Tsukinowa-cho,Otsu-city,Shiga,Japan
077-548-2238
hqchemo@belle.shiga-med.ac.jp
1st name | |
Middle name | |
Last name | EIJI Mekata |
Shiga University of Medical Science
Department of surgery
Seta Tsukinowa-cho,Otsu-city,Shiga,Japan
077-548-2238
hqchemo@belle.shiga-med.ac.jp
NPO FMPC (Future Medicine Promoting Consortium)
NPO FMPC (Future Medicine Promoting Consortium)
Other
NO
2013 | Year | 05 | Month | 23 | Day |
Unpublished
Open public recruiting
2012 | Year | 12 | Month | 25 | Day |
2013 | Year | 05 | Month | 29 | Day |
observational study
2013 | Year | 05 | Month | 23 | Day |
2014 | Year | 05 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012440